Ayah Ghazi Al-Qasrawi: How Should Sepsis-Induced DIC Be Managed in Patients Receiving Thienopyridines
Ayah Ghazi Al-Qasrawi, Pediatric Resident at Jordanian Royal Medical Services, shared on LinkedIn:
”What is the appropriate management approach for a patient receiving thienopyridines (clopidogrel or prasugrel), which irreversibly inhibit the platelet P2Y12 receptor, who develops sepsis-induced disseminated intravascular coagulation (DIC)?
I think the platelet transfusion could be a part of treatment.
Thienopyridines such as Clopidogrel and Prasugrel irreversibly inhibit the platelet P2Y12 receptor, preventing ADP-mediated platelet activation and clot formation.
Because the inhibition is irreversible, the antiplatelet effect persists for the entire lifespan of the platelet, approximately 7–10 days.
Antiplatelet thienopyridines (such as clopidogrel and prasugrel) irreversibly affect platelet function, but they do not affect platelet count.
In severe sepsis–associated DIC, management should primarily focus on treating the underlying infection and correcting clinically significant coagulopathy.
Platelet transfusion may be considered when there is active bleeding, high bleeding risk, need for invasive procedures, or severe thrombocytopenia.
In patients receiving thienopyridines, transfused platelets may help restore hemostatic function because the newly transfused platelets are initially uninhibited.
However, platelet transfusion is not routinely indicated based only on abnormal laboratory findings and should be guided by the overall clinical picture, including bleeding severity, platelet count, ongoing consumption, and thrombotic risk.
Adjunctive therapies:
IVIG is generally not recommended for routine treatment of sepsis-associated DIC unless there is suspicion of an additional immune-mediated platelet disorder.
Desmopressin (DDAVP) may be considered in selected cases of significant antiplatelet-associated bleeding to improve platelet adhesion, although evidence remains limited and it is not standard therapy for DIC. ( I think )
Additional supportive measures such as fresh frozen plasma or cryoprecipitate may be required depending on PT/aPTT prolongation and fibrinogen levels.”
Stay updated with Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health